Solventum Co. (NYSE:SOLV) Shares Bought by State Street Corp

State Street Corp lifted its stake in shares of Solventum Co. (NYSE:SOLV) by 3.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,107,550 shares of the company’s stock after purchasing an additional 185,938 shares during the quarter. State Street Corp owned about 3.54% of Solventum worth $425,818,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Tokio Marine Asset Management Co. Ltd. boosted its position in Solventum by 4.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares in the last quarter. National Bank of Canada FI raised its stake in shares of Solventum by 4.0% during the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock worth $314,000 after buying an additional 236 shares during the last quarter. IVC Wealth Advisors LLC raised its stake in shares of Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after buying an additional 318 shares during the last quarter. KKM Financial LLC boosted its position in shares of Solventum by 7.9% in the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after buying an additional 319 shares in the last quarter. Finally, Copeland Capital Management LLC acquired a new stake in Solventum in the 3rd quarter valued at about $26,000.

Analyst Upgrades and Downgrades

SOLV has been the topic of several recent research reports. Mizuho initiated coverage on shares of Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target on the stock. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. Stifel Nicolaus initiated coverage on Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price target for the company. Piper Sandler upped their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Finally, Morgan Stanley increased their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Solventum presently has an average rating of “Hold” and a consensus target price of $68.29.

Solventum Stock Up 1.0 %

Shares of NYSE:SOLV opened at $70.64 on Tuesday. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The stock’s 50-day moving average price is $70.71 and its two-hundred day moving average price is $62.96. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.